b 581 has been researched along with farnesol in 1 studies
Studies (b 581) | Trials (b 581) | Recent Studies (post-2010) (b 581) | Studies (farnesol) | Trials (farnesol) | Recent Studies (post-2010) (farnesol) |
---|---|---|---|---|---|
17 | 0 | 3 | 1,161 | 9 | 404 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 1 (100.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Brenner, DA; Cox, AD; Der, CJ; Garcia, AM; Kowalczyk, JJ; Lewis, MD; Westwick, JK | 1 |
1 other study(ies) available for b 581 and farnesol
Article | Year |
---|---|
The CAAX peptidomimetic compound B581 specifically blocks farnesylated, but not geranylgeranylated or myristylated, oncogenic ras signaling and transformation.
Topics: 3T3 Cells; Animals; Cell Transformation, Neoplastic; Diterpenes; DNA-Binding Proteins; ets-Domain Protein Elk-1; Farnesol; Mice; Myristic Acid; Myristic Acids; Oligopeptides; Oncogene Protein p21(ras); Protein Prenylation; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-jun; Retroviridae Proteins, Oncogenic; Signal Transduction; Transcription Factors; Transcription, Genetic | 1994 |